Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (September 2022)
25 slides from Matinas Biopharma's investor presentation, Sep 13, 2022
Slide 1: Corporate Presentation September 2022
MATINAS ; Corporate Presentation BIOPHARMA September 2022
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other sta
Slide 3: Lipid Nanocrystal (LNC) Platform: Clinically Validated Intracellular Delivery
Lipid Nanocrystal (LNC) Platform: Clinically Validated Intracellular Delivery Next generation platform delivery beyond LNPs and viral vectors GQ &® © Extra-hepatic Targeting = Selective uptake by phagocytic cells (e.g. macrophages) and cells with externalized phosphatidylserine (e.g, injured, inflam
Slide 4: What Are Lipid Nanocrystals (LNCs) and How Do They Deliver Drugs?
What Are Lipid Nanocrystals (LNCs) and How Do They Deliver Drugs? NC Structure LNCs achieve effective intracellular delivery via BOTH Calcium (Ca**) ions Phosphatidylserine (PS) crystalline shell, engineered to self-assemble into nano-erystals in the presence of Ca”* Drug Cargo PS on the outer cell
Slide 5: Physiologic Importance of Phosphatidylserine on the Surface of Cells
Physiologic Importance of Phosphatidylserine on the Surface of Cells Cell membrane Normally, PS is confined to the inner layer (facing cytosol) | | \i\\\}} Cell membrane Phosphatidylserine With “activation” PS moves from the inner layer to the outer layer (cell membrane) Expression of PS on Multiple
Slide 6: Unlocking the Full Potential of the LNC Platform
Unlocking the Full Potential of the LNC Platform Matinas is working internally and with third parties to push the boundaries of LNC delivery Past Intracellular Delivery of Nucleic Acids siRNA ASO Oral Formulations of Anti-infectives MAT2203 MAT2501. A mRNA DNA Ex ogo c € Broad Therapeutic Applicatio
Slide 7: LNC: The Next Generation of Intracellular Nucleic Acid Delivery
LNC: The Next Generation of Intracellular Nucleic Acid Delivery Sorat Dosing 3 e Targeting Payload size Safety / Redosin Ay Stability wa @ Lipid Nanocrystals Adeno-Associated Virus Lipid Nanoparticle (LNCs) (AAV) (LNP) 4 2 Proven Assets xX Not Orally Available x Not Orally Available Phagocytes & Loc
Slide 8: Matinas' Pipeline and Discovery Programs: Internal and Collaborative
Matinas’ Pipeline and Discovery Programs: Internal and Collaborative Program Indication Discovery Preclinical Phase 1 Phase 2 Collaborators cs 7 =i aaa MaT2203 fee ENACT Cohort 4 (Top-line Results 04.2022) LNC-Amphotericin B Teneo (oral) pete In vivo studies ongoing MAT2501. Non-tuberculous a LNC-Am
Slide 9: MAT2203 Oral Amphotericin B
MAT2203 ORAL AMPHOTERICIN B Phase 3 set to commence Q1 2023 a. MATINAS.
Slide 10: MAT2203: Unmet Medical Need in Invasive Fungal Infections
MAT2203: Unmet Medical Need in Invasive Fungal Infections Available systemically and orally Cost- effective ells Fungicidal THE IDEAL ANTIFUNGAL AGENT Penetrates well into Well-tol infected tissues ell-tolerated and safe Low propensity for resistance Minimal drug-drug interactions for the treatment
Slide 11: MAT2203: A Novel Approach with a Proven Therapeutic Agent
MAT2203: A Novel Approach with a Proven Therapeutic Agent MAT2203 Oral amphotericin B formulation utilizing LNCs Initial indication in cryptococcal meningitis Efficient intracellular delivery to immune cells and delivery directly to infected tissues IMPROVED PROFILE LNC formulation enables oral admi
Slide 12: Cryptococcal Meningitis Is a Severe Fungal Infection with High Mortality
2 Cryptococcal Meningitis Is a Severe Fungal Infection with High Mortality Deadly invasive fungal infection of the brain Typically affects immunocompromised individuals 10-20% 7,200 of all HIV-related Estimated incidence in deaths US and ES combined 180,000 deaths per year worldwide ; 30% Mortality
Slide 13: MAT2203: EnACT Phase Study
MAT2203: EnACT Phase 2 Study EnACT INDUCTION (2 WEEKS) EARLY CONSOLIDATION (4 WEEKS) COHORT 1. MAT2203 + Fluconazole @ ovki Eee Ee ‘5 days 10 days MAT2203 MAT2203 + Fluconazole (2) COHORT 2 WAMB 1.8 g/day 1.2 g/day (n=40) 2 days 13 days MAT2203 MAT2203 + Fluconazole @ coHorrs vos) -\ COHORT4 MAT2203
Slide 14: MAT2203: EnACT Phase Study Results
MAT2203: EnACT Phase 2 Study Results ENACT Clinical Data Validates the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity & : ooo ooo, e e e e e Exceeded the primary All patients completing No breakthrough i : MAT2203 was safe and endpoint hres told induction achieved ifecti
Slide 15: EnACT Phase III Pivotal Study Design
6 EnACT Phase III Pivotal Study Design Assess MAT2203 as step-down induction and consolidation therapy after 2 days of IV AMB Validate results observed in EnACT Randomized 1:1:1 ratio to 1 of 2 MAT2203 arms or SoC SCREENING ‘MAT2203 Induction/ Consolidation n=90 ‘TREATMENT Fluconazole 800 mg/day MAT
Slide 16: Value Proposition for MAT2203
Value Proposition for MAT2203 Oral Administration Lack of Nephrotoxicity enables earlier release ais enables longer treatment duration from hospital or avoidance supported by oral of home infusion administration LIFE CYCLE MANAGEMENT Prophylaxis in Transplant Patients Overall Development Strategy: C
Slide 17: MAT2203: Addressing a $550M+ Market with Active Regional and Global Pharma
w MAT2203: Addressing a $550M+ Market with Active Regional and Global Pharma MAT2203 Planned LCM expected to reach $500M- $750M in US Revenue Cryptococcal Meningitis Invasive fungal infections Prophylaxis in IC patients CIDARA mun ‘September 2019 Cidara licenses ex-US / ex-Japan rights of rezafungin
Slide 18: MAT2501 and Ongoing Partnership Programs
MAT2501 & ONGOING PARTNERSHIP PROGRAMS a MATINAS.
Slide 19: MAT2501: NTM Program Overview and SAD Topline Results
MAT2501: NTM Program Overview and SAD Topline Results * NTM organisms are a frequent cause of challenging pulmonary infections, especially in patients with pre- existing inflammatory lung diseases such as cystic fibrosis .. * LNC formulation enables oral administration, bioavailability and potential
Slide 20: LNC-remdesivir: In vivo Assessment of Efficacy Against SARS-CoV-2
Percent Starting Weight 20 LNC-remdesivir: /n vivo Assessment of Efficacy Against SARS-CoV-2 @G GILEAD In mice infected with SARS-CoV-2, oral LNC-Remdesivir reduced viral lung titers (beginning on Day 2), improved congestion scores, and mitigated weight loss 10 100: Congestion Score 70 o 1 2 3 4 6 D
Slide 21: LNC-mRNA: Exclusive Research Collaboration with BioNTech
LNC-mRNA: Exclusive Research Collaboration with BioNTech MATINAS © BIOPHARMA Focused on mRNA and certain other nucleic acids = $2.75 million upfront exclusive access fee plus research funding = Ongoing license agreement negotiations = BioNTech’s mRNA vaccine development expertise combined with Matin
Slide 22: Expanding LNC Intellectual Property Portfolio
2 Expanding LNC Intellectual Property Portfolio Continuingly increasing our patent suite to increase protection and exclusivity years of exclusivity (QIDP & ODD status) T| MAT2203 & 2501 potentially entitled to 12+ + LY Global Platform IP base protection out to 2037 with 20 patents issued in last 5
Slide 23: Experienced Leadership Team
Experienced Leadership Team Executive Team Jerome D. Jabbour, J. Thomas J. Hoover, MBA Theresa Matkovits, Ph. Se4ene *Feunovion W Novartis G@ Reliant’ © DPS Bice Keith A, Kucinski, CPA, MBA Hul Liu, Ph.D., MBA Raphael J. Mannino, Ph.D. Chief Financial Officer Chief Technical ortcer Chief Scientific
Slide 24: Matinas Has Executed on Multiple Milestones.
2 Matinas Has Executed on Multiple Milestones. MAT2203 LNC Platform & Collaborations 1H 2022 Milestones & Catalysts With More to Come 2H 2022 and Beyond Milestones & Catalysts NNN NAAN FDA approval on Phase 3 of EnACT Initiate preclinical studies in C. auris and mucormycosis Data available from Phas
Slide 25: Matinas BioPharma Holdings
Matinas BioPharma Holdings M A l | N A S (NYSE AMER: MTNB) } 1545 Route 206 South Suite 302 BIOPHARMA Bedminster, NJ 07921 (908) 484-8805 www.matinasbiopharma.com
Matinas BioPharma Holdings — Investor Presentation (September 2022) on 6ix